GlassScriptPhysician profile
Bheema Singu
NPI 1922204528
$5,147.76
in general payments reported to CMS, 2019-2025
32 companies · $640 in 2025
The $640 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $602 · 2021: $528 · 2022: $419 · 2023: $607 · 2024: $1,432 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432 · Gift: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.40 |
| Gift | $245.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,340.90 | 2019-2025 | Linzess, Viberzi, Mavyret |
| Ironwood Pharmaceuticals, INC | $784.26 | 2019-2024 | Linzess |
| Braintree Laboratories, INC. | $369.78 | 2019-2024 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $285.10 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $271.53 | 2021-2025 | Exalt Model D, Hydratome Rx 44 |
| Nestle Healthcare Nutrition INC. | $227.26 | 2022-2023 | |
| Medtronic, INC. | $159.05 | 2022-2024 | Endoflip, Nexpowder, Pillcam |
| Allergan, INC. | $151.02 | 2019 | |
| Aimmune Therapeutics, INC. | $143.86 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.12 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $126.75 | 2024 | |
| Janssen Pharmaceuticals, INC | $124.44 | 2024 | Xarelto |
| Ardelyx, INC. | $115.68 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $114.43 | 2019-2020 | |
| Madrigal Pharmaceuticals | $111.94 | 2024 | Rezdiffra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $107.39 | 2023-2024 | Dupixent |
| Celgene Corporation | $101.00 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $81.64 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $70.88 | 2019-2025 | |
| Micro-Tech Endoscopy USA, INC. | $39.16 | 2020 | |
| Ferring Pharmaceuticals INC. | $34.66 | 2019-2020 | |
| Olympus America INC. | $31.39 | 2020-2024 | Endoclot Phs |
| Vivus LLC | $30.44 | 2021 | |
| Ambu INC. | $30.21 | 2020 | |
| Shionogi INC | $28.11 | 2019 | |
| Enterra Medical, INC. | $21.40 | 2023 | |
| Novo Nordisk INC | $21.36 | 2025 | Wegovy |
| Pfizer INC. | $20.73 | 2025 | |
| Exact Sciences Corporation | $19.01 | 2025 | The Cologuard Plus Collection Kit |
| Redhill Biopharma INC. | $17.37 | 2020 | |
| Organon LLC | $14.18 | 2024 | |
| Ucb, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bheema Singu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.